(Q40677459)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8040144%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

review article

1 reference

title

Topoisomerase I inhibitors. An overview of the camptothecin analogs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8040144%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

author name string

H A Burris

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8040144%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

S M Fields

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8040144%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

publication date

1 April 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8040144%20AND%20SRC:MED&resulttype=core&format=json

Hematology / Oncology Clinics of North America

23 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8040144%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8040144%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8040144%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

page(s)

333-355

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8040144%20AND%20SRC:MED&resulttype=core&format=json

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

23 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

Characterization of camptothecin-resistant chinese hamster lung cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

New natural products in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

The current status of camptothecin analogues as antitumor agents

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

Topoisomerases, new targets in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930176-X

7 January 2021

10.1016/S0889-8588(18)30176-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8040144%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

1 reference